List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9513928/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Haploidentical Stem Cell Transplantation After TCR-αβ+ and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease. Transplantation and Cellular Therapy, 2022, 28, 394.e1-394.e9.	1.2	10
2	¹³¹ lâ€Metaâ€iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28775.	1.5	5
3	P1832IGG4 RELATED DISEASE: NEPHROPATHY AND BONE MARROW FAILURE IN A 2 YEAR-OLD CHILD. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
4	Imatinib melylate as secondâ€line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. Pediatric Pulmonology, 2020, 55, 631-637.	2.0	11
5	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	4.1	30
6	Use of eltrombopag in aplastic anemia in Europe. Annals of Hematology, 2019, 98, 1341-1350.	1.8	30
7	Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 743-748.	2.0	12
8	Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association–Hematopoietic Stem Cell Transplantation Group. Biology of Blood and Marrow Transplantation, 2019, 25, 313-320.	2.0	35
9	Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases. Biology of Blood and Marrow Transplantation, 2018, 24, 1088-1093.	2.0	17
10	RAG deficiency with ALPS features successfully treated with TCRαβ/CD19 cell depleted haploidentical stem cell transplant. Clinical Immunology, 2018, 187, 102-103.	3.2	12
11	Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1126-1136.	10.7	58
12	Allogeneic hematopoietic stem cell transplantation in congenital disorders: A single enter experience. Pediatric Transplantation, 2017, 21, e12997.	1.0	3
13	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	5.8	103
14	CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever. Frontiers in Immunology, 2017, 8, 2015.	4.8	31
15	Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AlEOP-GITMO Retrospective Multicenter Study. Biology of Blood and Marrow Transplantation. 2016. 22. 902-909.	2.0	69
16	Long-term Outcome of a Successful Cord Blood Stem Cell Transplant in Mevalonate Kinase Deficiency. Pediatrics, 2015, 135, e211-e215.	2.1	30
17	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. British Journal of Haematology, 2015, 169, 711-718.	2.5	56
18	Autoimmune Hematological Diseases after Allogeneic Hematopoietic Stem Cell Transplantation in Children: An Italian Multicenter Experience. Biology of Blood and Marrow Transplantation, 2014, 20, 272-278.	2.0	75

#	Article	IF	CITATIONS
19	Role of Acute Graft-Versus-Host Disease in the Risk of Bacteremia and Invasive Fungal Disease after Allogeneic Hemopoietic Stem Cell Transplantation in Children. Results from a Single-Center Observational Study. Biology of Blood and Marrow Transplantation, 2014, 20, 1068-1073.	2.0	22
20	Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. British Journal of Haematology, 2014, 165, 673-681.	2.5	61
21	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
22	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica, 2013, 98, 1273-1281.	3.5	30
23	Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. American Journal of Hematology, 2013, 88, 868-873.	4.1	10
24	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of Blood and Marrow Transplantation, 2012, 18, 852-860.	2.0	18
25	Acute graftâ€versusâ€host disease in pediatric allogeneic hematopoietic stem cell transplantation. Singleâ€center experience during 10 yr. Pediatric Transplantation, 2012, 16, 887-893.	1.0	22
26	Hematopoietic Cell Transplantation for Children with High Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Report From the Italian Association of Pediatric Hematology and Oncology (AIEOP) Registry Blood, 2012, 120, 3036-3036.	1.4	0
27	A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2. Journal of Virological Methods, 2011, 178, 98-105.	2.1	13
28	HHVâ€8â€related visceral Kaposi's sarcoma following allogeneic HSCT: Report of a pediatric case and literature review. Pediatric Transplantation, 2011, 15, E8-11.	1.0	19
29	Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Human Mutation, 2010, 31, E1071-E1080.	2.5	77
30	Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica, 2010, 95, 976-982.	3.5	183
31	Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation. Acta Haematologica, 2010, 124, 19-22.	1.4	5
32	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. Biology of Blood and Marrow Transplantation, 2010, 16, 1293-1301.	2.0	165
33	Telomere length of donors influences granulocyte recovery in children after hematopoietic stem cell transplantation. Annals of Hematology, 2009, 88, 1029-1031.	1.8	7
34	Unrelated hematopoietic stem cell transplantation for Cernunnosâ€XLF deficiency. Pediatric Transplantation, 2009, 13, 785-789.	1.0	30
35	An unusual pattern of B-cell immunological reconstitution after allogeneic stem cell transplantation: A possible correlation with CMV reactivation?. Pediatric Transplantation, 2009, 13, 1050-1052.	1.0	2
36	Early (Day â [^] 7) versus Conventional (Day â [^] 1) Inception of Cyclosporine-A for Graft-versus-Host Disease Prophylaxis after Unrelated Donor Hematopoietic Stem Cell Transplantation in Children. Long-Term Results of an AIEOP Prospective, Randomized Study. Biology of Blood and Marrow Transplantation, 2009, 15, 741-748.	2.0	4

#	Article	IF	CITATIONS
37	Osteochondroma after Hematopoietic Stem Cell Transplantation in Childhood. An Italian Study on Behalf of the AIEOP-HSCT Group. Biology of Blood and Marrow Transplantation, 2009, 15, 1271-1276.	2.0	18
38	LOW DOSAGE CIDOFOVIR WITHOUT PROBENECID AS TREATMENT FOR BK VIRUS HAMORRHAGIC CYSTITIS AFTER HEMOPOIETIC STEM CELL TRANSPLANT. Pediatric Infectious Disease Journal, 2009, 28, 55-57.	2.0	35
39	Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatric Transplantation, 2008, 12, 117-120.	1.0	19
40	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, The, 2008, 371, 1579-1586.	13.7	2,474
41	Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica, 2008, 93, 1694-1701.	3.5	62
42	Allogeneic Stem Cell Transplantation for Children With Acute Myeloid Leukemia in Second Complete Remission. Journal of Pediatric Hematology/Oncology, 2008, 30, 575-583.	0.6	16
43	Risk for Secondary Thyroid Carcinoma After Hematopoietic Stem-Cell Transplantation: An EBMT Late Effects Working Party Study. Journal of Clinical Oncology, 2007, 25, 2449-2454.	1.6	125
44	Risk Factors and Severe Outcome in Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation, 2006, 82, 638-644.	1.0	144
45	Helicobacter pylori as cause of gastrointestinal disease in children with hemato-oncologic diseases. Pediatric Blood and Cancer, 2006, 47, 89-91.	1.5	2
46	Gain of 1q in pediatric myelodysplastic syndromes. Leukemia Research, 2006, 30, 1437-1441.	0.8	9
47	Mutations in OSTM1 (Grey Lethal) Define a Particularly Severe Form of Autosomal Recessive Osteopetrosis With Neural Involvement. Journal of Bone and Mineral Research, 2006, 21, 1098-1105.	2.8	97
48	Intractable Epilepsy Secondary to Cyclosporine Toxicity in Children Undergoing Allogeneic Hematopoietic Bone Marrow Transplantation. Journal of Child Neurology, 2006, 21, 861-866.	1.4	19
49	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease Blood, 2006, 108, 2918-2918.	1.4	4
50	Osteonecrosis after allogeneic stem cell transplantation in childhood. A case-control study in Italy. Haematologica, 2006, 91, 1096-9.	3.5	39
51	Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
52	Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1568-1575.	0.8	76
53	Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia. Pediatric Transplantation, 2005, 9, 797-800.	1.0	6
54	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 2005, 105, 410-419.	1.4	291

#	Article	IF	CITATIONS
55	Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors. Molecular Immunology, 2005, 42, 405-411.	2.2	19
56	Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells. Cancer Research, 2004, 64, 9180-9184.	0.9	224
57	MLL-MLLT10 fusion in acute monoblastic leukemia: variant complex rearrangements and 11q proximal breakpoint heterogeneity. Cancer Genetics and Cytogenetics, 2004, 152, 108-112.	1.0	15
58	Analysis of the activating receptors and cytolytic function of human natural killer cells undergoingin vivo differentiation after allogeneic bone marrow transplantation. European Journal of Immunology, 2004, 34, 455-460.	2.9	48
59	The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. European Journal of Immunology, 2004, 34, 3028-3038.	2.9	83
60	Cytomegalovirus infection after bone marrow transplantation in children. Human Immunology, 2004, 65, 416-422.	2.4	69
61	Surgery for Acute Graft-Versus-Host Disease of the Bowel: Description of a Pediatric Case. Journal of Pediatric Hematology/Oncology, 2004, 26, 441-443.	0.6	11
62	Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. British Journal of Haematology, 2003, 122, 118-127.	2.5	174
63	Genotype-Phenotype Relationship in Human ATP6i-Dependent Autosomal Recessive Osteopetrosis. American Journal of Pathology, 2003, 162, 57-68.	3.8	97
64	Long-lasting Hypogammaglobulinemia Following Rituximab Administration for Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disease Preemptive Therapy. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 9-10.	1.8	26
65	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood, 2003, 103, 1417-1424.	1.4	195
66	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood, 2002, 100, 1192-1200.	1.4	201
67	Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO). Haematologica, 2002, 87, 51-7.	3.5	9
68	Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica, 2002, 87, 1274-80.	3.5	18
69	Immunohistochemical Study of Skin Lesions in Acute and Chronic Graft Versus Host Disease Following Bone Marrow Transplantation. American Journal of Surgical Pathology, 1997, 21, 23-34.	3.7	35
70	Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Cancer, 1992, 70, 1625-1633.	4.1	97
71	Treatment of advanced neuroblastoma with i-131 meta-iodobenzylguanidine. Cancer, 1991, 67, 922-928.	4.1	60
72	Cytogenetic and molecular study of two human neuroblastoma cell lines. Cancer Genetics and Cytogenetics, 1988, 30, 225-231.	1.0	38

#	Article	IF	CITATIONS
73	Resistant and relapsing neuroblastoma: Improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum. Medical and Pediatric Oncology, 1987, 15, 18-23.	1.0	18